
|Articles|February 1, 2005
Cooperation cuts FDA approval times
Kissimmee, Fla. — The time it takes for the U.S. Food and Drug Administration (FDA) approval of a new dermatology drug or treatment depends on many factors, including how closely pharmaceutical companies cooperate with the agency.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5


















